-
1
-
-
38949132621
-
-
Russian source
-
Russian source
-
-
-
-
2
-
-
38949134752
-
-
Russian source
-
Russian source
-
-
-
-
3
-
-
38949148189
-
-
Russian source
-
Russian source
-
-
-
-
4
-
-
38949160713
-
-
Russian source
-
Russian source
-
-
-
-
5
-
-
0032916601
-
Prevalence and clinical correlates of psychotic symptoms in Parkinson's disease
-
Aarsland D., Larsen J.P., Cumming J.L. et al. Prevalence and clinical correlates of psychotic symptoms in Parkinson's disease. Arch Neurol 1999; 56: 3: 595-601.
-
(1999)
Arch Neurol
, vol.56
, Issue.3
, pp. 595-601
-
-
Aarsland, D.1
Larsen, J.P.2
Cumming, J.L.3
-
6
-
-
0035957311
-
Risk of dementia in Parkinson's Disease: A community-based prospective study
-
Aarsland D., Andersen K., Larsen J. P. et al. Risk of dementia in Parkinson's Disease: A community-based prospective study. Neurology 2001; 56: 6: 730-736.
-
(2001)
Neurology
, vol.56
, Issue.6
, pp. 730-736
-
-
Aarsland, D.1
Andersen, K.2
Larsen, J.P.3
-
7
-
-
0142091310
-
Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia
-
Aarsland D., Hutchinson M., Larsen J.P. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriat Psychiat 2003; 18: 10: 937-941.
-
(2003)
Int J Geriat Psychiat
, vol.18
, Issue.10
, pp. 937-941
-
-
Aarsland, D.1
Hutchinson, M.2
Larsen, J.P.3
-
8
-
-
0033668441
-
Delusions associated with elevated muscarinic binding in dementia with Lewy bodies
-
Bollard C., Piggott M., Johnson M. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol 2000; 48: 6: 868-876.
-
(2000)
Ann Neurol
, vol.48
, Issue.6
, pp. 868-876
-
-
Bollard, C.1
Piggott, M.2
Johnson, M.3
-
9
-
-
0033572972
-
Caregiving as a risk factor for mortality: The Caregiver Health Effects Study
-
Beach S.R., Schulz R. Caregiving as a risk factor for mortality: the Caregiver Health Effects Study. JAMA 1999; 282: 23: 2215-2219.
-
(1999)
JAMA
, vol.282
, Issue.23
, pp. 2215-2219
-
-
Beach, S.R.1
Schulz, R.2
-
10
-
-
0347385143
-
Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: An in vivo positron emission tomographic study
-
Bohnen N.I., Kaufer D.I., Ivanco L.S. et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003; 60: 12: 1745-1748.
-
(2003)
Arch Neurol
, vol.60
, Issue.12
, pp. 1745-1748
-
-
Bohnen, N.I.1
Kaufer, D.I.2
Ivanco, L.S.3
-
11
-
-
32844471835
-
Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia
-
Bohnen N.I., Kaufer D.I., Hendrickson R. et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol 2005; 253: 2: 242-247.
-
(2005)
J Neurol
, vol.253
, Issue.2
, pp. 242-247
-
-
Bohnen, N.I.1
Kaufer, D.I.2
Hendrickson, R.3
-
12
-
-
0026355995
-
Cognitive impairment and dementia in Parkinson's disease: A controlled study
-
Boyd J.L., Cruickshank C.A., Kenn C. W. et al. Cognitive impairment and dementia in Parkinson's disease: a controlled study. Psychol Med 1991; 21: 3: 911-921.
-
(1991)
Psychol Med
, vol.21
, Issue.3
, pp. 911-921
-
-
Boyd, J.L.1
Cruickshank, C.A.2
Kenn, C.W.3
-
13
-
-
0036040074
-
Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: A case series
-
Bullock R., Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin 2002; 18: 5: 258-264.
-
(2002)
Curr Med Res Opin
, vol.18
, Issue.5
, pp. 258-264
-
-
Bullock, R.1
Cameron, A.2
-
14
-
-
0035376503
-
Dopaminomimetic psychosis in Parkinson's disease: First symptom of early dementia?
-
Catalan-Alonso M.J., Del Val J. Dopaminomimetic psychosis in Parkinson's disease: first symptom of early dementia? Rev Neurol 2001; 32: 11: 1085-1087.
-
(2001)
Rev Neurol
, vol.32
, Issue.11
, pp. 1085-1087
-
-
Catalan-Alonso, M.J.1
Del Val, J.2
-
15
-
-
0027985334
-
The Neuropsychiatrie Inventory: Comprehensive assessment of psychopathology in dementia
-
Cummings J.L., Mega M., Gray K. et al. The Neuropsychiatrie Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 12: 2308-2314.
-
(1994)
Neurology
, vol.44
, Issue.12
, pp. 2308-2314
-
-
Cummings, J.L.1
Mega, M.2
Gray, K.3
-
16
-
-
0036625325
-
The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities
-
Da Cunha C., Angelucci M.E., Conteras N. S. et al. The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities. Cell Mol Neurobiol 2002; 22: 3: 227-237.
-
(2002)
Cell Mol Neurobiol
, vol.22
, Issue.3
, pp. 227-237
-
-
Da Cunha, C.1
Angelucci, M.E.2
Conteras, N.S.3
-
17
-
-
0348048688
-
The role of olanzapine in Parkinsonian dopaminergic psychosis
-
Duran Ferreras E., Chacon J., Duran Quintana J.A. The role of olanzapine in Parkinsonian dopaminergic psychosis. Rev Neurol 2002; 35: 7: 691-696.
-
(2002)
Rev Neurol
, vol.35
, Issue.7
, pp. 691-696
-
-
Duran Ferreras, E.1
Chacon, J.2
Duran Quintana, J.A.3
-
18
-
-
0346749726
-
-
Edwards K.R., Hershey L., Wray L. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis. Dement Geriat Cogn Disord 2004; 17: Supll 1: 40-48.
-
Edwards K.R., Hershey L., Wray L. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis. Dement Geriat Cogn Disord 2004; 17: Supll 1: 40-48.
-
-
-
-
19
-
-
0028109336
-
The US economic and social costs of Alzheimer's disease revisited
-
Ernst R.L., Hay J. W. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health 1994; 84: 8: 1261-1264.
-
(1994)
Am J Public Health
, vol.84
, Issue.8
, pp. 1261-1264
-
-
Ernst, R.L.1
Hay, J.W.2
-
20
-
-
0036276359
-
Donepezil in the treatment of hallucinations and delusions in Parkinson's disease
-
Fabbrini G., Barbanti P., Aurilia C. et al. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci 2002; 23: 1: 41-43.
-
(2002)
Neurol Sci
, vol.23
, Issue.1
, pp. 41-43
-
-
Fabbrini, G.1
Barbanti, P.2
Aurilia, C.3
-
21
-
-
0342424352
-
Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors
-
Fenelon G., Mahieux F., Huon R. et al. Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors. Brain 2000; 123: 7: 733-745.
-
(2000)
Brain
, vol.123
, Issue.7
, pp. 733-745
-
-
Fenelon, G.1
Mahieux, F.2
Huon, R.3
-
23
-
-
23644450772
-
Frontal dysfunction contributes to the genesis of hallucinations in non-demented Parkinsonian patients
-
Grossi D., Trojano L., Pellecchia M.T. Frontal dysfunction contributes to the genesis of hallucinations in non-demented Parkinsonian patients. Int J Geriat Psychiat 2005; 20: 7: 668-673.
-
(2005)
Int J Geriat Psychiat
, vol.20
, Issue.7
, pp. 668-673
-
-
Grossi, D.1
Trojano, L.2
Pellecchia, M.T.3
-
24
-
-
0036260184
-
Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: A 6-[18F]fluoro-L-dopa PET study
-
Ito K., Nagano-Saito A., Kato T. et al. Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study. Brain 2002; 125: 6: 1358-1365.
-
(2002)
Brain
, vol.125
, Issue.6
, pp. 1358-1365
-
-
Ito, K.1
Nagano-Saito, A.2
Kato, T.3
-
25
-
-
0842325101
-
Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease
-
Leroi I., Brandt J., Reich S. G. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriat Psychiat 2004; 19: 1: 1-8.
-
(2004)
Int J Geriat Psychiat
, vol.19
, Issue.1
, pp. 1-8
-
-
Leroi, I.1
Brandt, J.2
Reich, S.G.3
-
26
-
-
33645834092
-
Correlation of visual hallucinations with occipital rCBF changes by donepezil in DLB
-
Mori T., Ikeda M., Fukuhara R. Correlation of visual hallucinations with occipital rCBF changes by donepezil in DLB. Neurology 2006; 66: 6: 935-937.
-
(2006)
Neurology
, vol.66
, Issue.6
, pp. 935-937
-
-
Mori, T.1
Ikeda, M.2
Fukuhara, R.3
-
27
-
-
0032977982
-
Medication-induced hallucination and cerebral blood flow in Parkinson's disease
-
Okada K., Suyama N., Oguro H. et al. Medication-induced hallucination and cerebral blood flow in Parkinson's disease. J Neurol 1999; 246: 5: 365-368.
-
(1999)
J Neurol
, vol.246
, Issue.5
, pp. 365-368
-
-
Okada, K.1
Suyama, N.2
Oguro, H.3
-
29
-
-
0027208615
-
Cholinergic transmitter and neurotrophic activities in Lewy body dementia: Similarity to Parkinson's and distinction from Alzheimer disease
-
Perry E., Irving D., Kerwin J.M. et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease. Alzheitner Dis Assoc Disord 1993; 7: 2: 69-79.
-
(1993)
Alzheitner Dis Assoc Disord
, vol.7
, Issue.2
, pp. 69-79
-
-
Perry, E.1
Irving, D.2
Kerwin, J.M.3
-
30
-
-
0036868921
-
Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologie challenge with oral rivastigmine
-
Richard I.H., Justus A.W., Greig N.H. et al. Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologie challenge with oral rivastigmine. Clin Neuropharmacol 2002; 25: 6: 296-299.
-
(2002)
Clin Neuropharmacol
, vol.25
, Issue.6
, pp. 296-299
-
-
Richard, I.H.1
Justus, A.W.2
Greig, N.H.3
-
31
-
-
0036063168
-
-
Rosler M. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int J Clin Pract 2002; 127: Supll 1: 20-36.
-
Rosler M. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int J Clin Pract 2002; 127: Supll 1: 20-36.
-
-
-
-
32
-
-
3142547230
-
Cholinergic enhancement of frontal lobe activity in mild cognitive impairment
-
Saykin A.J., Wishart H.A., Rabin L.A. Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. Brain 2004; 127: 7: 1574-1583.
-
(2004)
Brain
, vol.127
, Issue.7
, pp. 1574-1583
-
-
Saykin, A.J.1
Wishart, H.A.2
Rabin, L.A.3
-
33
-
-
0030828946
-
Longitudinal analysis of multiple indicators of health decline among spousal caregivers
-
Shaw W.S., Patterson T.L., Semple S.J. Longitudinal analysis of multiple indicators of health decline among spousal caregivers. Ann Behav Med 1997; 19: 2: 101-109.
-
(1997)
Ann Behav Med
, vol.19
, Issue.2
, pp. 101-109
-
-
Shaw, W.S.1
Patterson, T.L.2
Semple, S.J.3
-
34
-
-
0036715245
-
Dementia in Parkinson disease: A proton magnetic resonance spectroscopy study
-
Summeifield C., Gomez-Anson B., Tolosa E. et al. Dementia in Parkinson disease: a proton magnetic resonance spectroscopy study. Arch Neurol 2002; 59: 9: 1415-1420.
-
(2002)
Arch Neurol
, vol.59
, Issue.9
, pp. 1415-1420
-
-
Summeifield, C.1
Gomez-Anson, B.2
Tolosa, E.3
-
35
-
-
0024372106
-
Clock drawing in Alzheimer's disease: A novel measure of dementia severity
-
Sunderland T., Hill J.L., Mellow A.M. et al. Clock drawing in Alzheimer's disease: a novel measure of dementia severity. J Am Geriat Soc 1989; 37: 5: 725-729.
-
(1989)
J Am Geriat Soc
, vol.37
, Issue.5
, pp. 725-729
-
-
Sunderland, T.1
Hill, J.L.2
Mellow, A.M.3
-
36
-
-
0034720864
-
A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group
-
Tariot P.N., Solomon P.R., Morris J.C. et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group Neurol 2000; 54: 12: 2269-2276.
-
(2000)
Neurol
, vol.54
, Issue.12
, pp. 2269-2276
-
-
Tariot, P.N.1
Solomon, P.R.2
Morris, J.C.3
-
37
-
-
33645749810
-
Visual dysfunction in Parkinson disease without dementia
-
Uc E.Y., Rizzo M., Anderson S.W. Visual dysfunction in Parkinson disease without dementia. Neurology 2005; 65: 12: 1907-1913.
-
(2005)
Neurology
, vol.65
, Issue.12
, pp. 1907-1913
-
-
Uc, E.Y.1
Rizzo, M.2
Anderson, S.W.3
-
39
-
-
12344253723
-
Increased risk of stroke during the use of olanzapine or risperidone in patients with dementia
-
Van Marum R.J., Jansen P.A. Increased risk of stroke during the use of olanzapine or risperidone in patients with dementia. Ned Tijdschr Geneeskd 2005; 149: 4: 165-167.
-
(2005)
Ned Tijdschr Geneeskd
, vol.149
, Issue.4
, pp. 165-167
-
-
Van Marum, R.J.1
Jansen, P.A.2
-
40
-
-
0037249095
-
Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson's disease
-
Woods S.P., Troster A.I. Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson's disease. J Int Neuropsychol Soc 2003; 9: 1: 17-24.
-
(2003)
J Int Neuropsychol Soc
, vol.9
, Issue.1
, pp. 17-24
-
-
Woods, S.P.1
Troster, A.I.2
-
41
-
-
0037337815
-
Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer's and Parkinson's diseases
-
Zarow C., Lyness S.A., Mortimer I.A., Chui H.C. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer's and Parkinson's diseases. Arch Neurol 2003; 60: 3: 337-341.
-
(2003)
Arch Neurol
, vol.60
, Issue.3
, pp. 337-341
-
-
Zarow, C.1
Lyness, S.A.2
Mortimer, I.A.3
Chui, H.C.4
-
42
-
-
4944239612
-
Cholinergic Drugs for Alzheimer's Disease Enhance in Vitro Dopamine Release
-
Zhang L., Zhou F., Dani J.A. Cholinergic Drugs for Alzheimer's Disease Enhance in Vitro Dopamine Release. Mol Pharmacol 2004; 66: 3: 538-544.
-
(2004)
Mol Pharmacol
, vol.66
, Issue.3
, pp. 538-544
-
-
Zhang, L.1
Zhou, F.2
Dani, J.A.3
|